In an upcoming book, Ruby Wang, a physician and biotech consultant in the U.K., makes the case that China's rapid progress in health technology is not a threat but an opportunity for the rest of the world. Drawing on her experience across both Western and Chinese medical systems, she argues that China's investments in artificial intelligence, genomics, and pharmaceutical development are producing tools that can address long-standing global health inequities.
Wang highlights how Chinese companies are using AI to speed up diagnostics and drug discovery, often at a fraction of the cost seen in Western markets. She contends that these efficiencies could make treatments more affordable and accessible in low- and middle-income countries, where price barriers are most acute. The book also points to China's vast clinical data pools as a resource for training algorithms that perform well across diverse populations.
At the same time, Wang cautions that these advances will only benefit the world if governments and firms share data and collaborate openly. She notes that geopolitical tensions risk fragmenting medical research, which would slow innovation everywhere. Her central message is that China's rise in health tech is a positive development, provided it is met with cooperation rather than isolation.